Statins and osteoporosis;Statiny a osteoporóza

Vnitrni Lekarstvi

Volumn 52, Issue 12, 2006, Pages 1190-1193

  Svejda P ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Bone density; Osteoporosis; Risk of fracture; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MORPHOGEN;

BONE METABOLISM; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY; DEMENTIA; DRUG MECHANISM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; OSTEOPOROSIS; PLEIOTROPY; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CALCIFICATION, PHYSIOLOGIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS;

EID: 33845626064     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Alberts AW, Chen J, Kuron G et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980; 77: 3957-3961.
2. Bauer DC, Mundy GR, Jamal SA et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 1999; 14: S179.
3. Edwards CJ, Hart DJ, Spector TD et al. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218-2219.
4. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: resuits from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082.
5. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37.
6. Chan KA, Andrade SE, Boles M et al. Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-2188.
7. Chung YS, Lee MD, Lee SK et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 1137-1142.
8. Karpf DB, Shapiro DR, Seeman E et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Group. JAMA 1997; 277: 1159-1164.
9. LaCroix AZ, Cauley JA, Jackson R et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res 2000; 15(Suppl 1): 1066.
10. Luckman SP, Hughes DE, Coxon FP et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
11. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340.
12. Meier CR, Schlienger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
13. Meier CR, Schlienger RG, Kraenzlin ME et al. Statins and the risk of fracture. JAMA 2000; 284: 1921-1922.
14. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.
15. Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. JAMA 2001; 284: 1921-1922.
16. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet 2001; 357: 509-512.
17. Rogers MJ Statins: ower lipids and better bones? Nat Med 2000; 6: 21-23.
18. Van Beek E, Pieterman E, Cohen L et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108-211.
19. Vogel G. Cholesterol-lowering drugs may boost bones. Science 1999; 286: 1825-1826.
20. Wang PS, Solomon DH, Mogun H et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-3216.
21. Watanabe S, Fukumoto S, Takeuchi Y et al. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001; 110: 584-587.
22. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269.